Immunotherapy Pair Lowers PSA in Advanced Prostate Cancer

In a small early trial, most men with heavily treated disease saw PSA drop at least 50%.

Updated on Nov. 7, 2026 in Cancer

Bold flat-color editorial illustration of pale amber cells gripping a dark cratered cell on a cream field, evoking immune attack on cancer.
A two-drug immunotherapy combination lowered PSA levels by at least 50% in most heavily treated men with advanced prostate cancer in a small early trial. AI Illustration. Upload story photo >

Early-stage trial data showed a combination of two investigational immunotherapies produced prostate-specific antigen (PSA) declines in men with advanced prostate cancer that had stopped responding to castration therapy. The results were presented at the 2026 SITC Annual Meeting, and the findings come from a small phase 1 cohort.

Why it matters

For men with metastatic castration-resistant prostate cancer, options narrow after multiple lines of treatment, so a new approach showing measurable PSA responses in heavily pretreated patients is a meaningful signal for the field. The data are preliminary, and whether this combination improves survival or quality of life remains to be shown in larger studies.

This is a phase 1 study of 15 patients in the recommended phase 2 regimen cohort, with a median of 4 prior lines of therapy, and PSA responses were measured against baseline rather than a control group. The early-stage design means the findings characterize safety and early activity, not effectiveness compared with standard care.

The players

University of Colorado School of Medicine

A leading academic medical school whose researchers contribute to oncology and urologic cancer studies, including the presenting physician's affiliated trial work.

UCHealth Tony Grampsas Urologic Cancer Care Clinic

A specialized clinic within UCHealth focused on the diagnosis and treatment of urologic cancers, including prostate cancer.

The details

The regimen pairs two bispecific immunotherapies, each designed to bring immune T-cells to tumor cells: pasritamig, given intravenously at 300 mg every 6 weeks after step-up dosing, targets KLK2, a protein found on prostate cells, while JNJ-87189401, given subcutaneously at 200 mg every 6 weeks starting on day 15, targets PSMA, a protein highly expressed on prostate cancer cells. Because both agents recruit T-cells to attack tumor cells, researchers track PSA as a marker of tumor response, and the study's safety data focused on cytokine release syndrome and neurotoxicity.

Timeline

  1. The phase 1 data were presented in 2026 at the SITC Annual Meeting.

  2. Pasritamig with or without JNJ-87189401 is being evaluated in the phase 3 KLK2-comPAS trial in late-line metastatic castration-resistant prostate cancer.

Health Landscape

Metastatic castration-resistant prostate cancer is treated after multiple lines of hormonal, chemotherapy, and radioligand therapy, where options are limited. Bispecific T-cell engagers like these are an emerging class being tested to add activity in this heavily pretreated population.

If you or someone close to you has advanced prostate cancer that has stopped responding to hormone therapy, these results are worth discussing with an oncologist, who can explain whether clinical trial enrollment is an appropriate option. Routine PSA monitoring remains the standard way clinicians track treatment response, and questions about trial eligibility should go to your treating team.

The takeaway

Early data suggest this immunotherapy combination can produce deep PSA responses in heavily pretreated prostate cancer, but the cohort is small and the findings remain preliminary. Men with advanced disease who want to know about emerging options should ask their oncologist about ongoing clinical trials.

Further reading

For broader context on how newer immunotherapies are being tested across tumor types, explore our Cancer coverage.